AGLE - Aeglea BioTherapeutics Inc
Close
12.01
0.970 8.077%
Share volume: 43,369
Last Updated: Mon 27 Nov 2023 10:00:00 PM CET
Pharmaceutical Preparation Manufacturing :
-2.88%
PREVIOUS CLOSE
CHG
CHG%
$11.04
0.97
8.79%
Summary score
42%
Profitability
50%
Dept financing
11%
Liquidity
47%
Performance
40%
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Long-term ratios 30-Sep-2019 - 30-Sep-2023
The data are presented for the financials results of the quarters of the last 4 years.
Return on equity
109.97%
Return on assets
-22.43%
Return on sales
-6919.06%
Return on invested capital
287.16%
Total debt ratio
28.85%
Debt ratio change over timeo
-0.86%
Current Ratio
5.44%
Quick Ratio
5.35%
Cash Position Ratio
4.44%
Short-term ratios 30-Sep-2022 - 30-Sep-2023
The data are presented for the financials results of the quarters of the last year.
Return on equity
510.1%
Return on assets
-36.02%
Return on sales
-14683.38%
Return on invested capital
229.33%
Total debt ratio
50.22%
Debt ratio change over timeo
-0.76%
Current Ratio
3.35%
Quick Ratio
3.35%
Cash Position Ratio
3.1%
Last quarter ratios 30-Sep-2023
The data are presented for the financials results of the last quarter.
Return on equity
-28.3%
Return on assets
-15.9%
Return on sales
0%
Return on invested capital
92.08%
Total debt ratio
31.63%
Debt ratio change over time
-0.66%
Current Ratio
4.59%
Quick Ratio
4.59%
Cash Position Ratio
4.54%
Performance ratios (change over 4 years) 30-Sep-2019 - 30-Sep-2023
The data are presented for the change financials results of the quarter of the last 4 years.
Return on equity
-90.48%
Return on assets
-110.51%
Return on sales
-2659.33%
Return on invested capital
43.86%
Total debt ratio
-86.21%
Debt ratio change over time
-0.86%
Current Ratio
1.87%
Quick Ratio
2.03%
Cash Position Ratio
1.44%
Compare in sector
The following table compares the individual analyzes for the other top 3 stocks within the same industry.
| Long-term ratios | AGLE | VLON | ELAT | RETA |
|---|---|---|---|---|
| Return on equity | 109.97% | 0% | 0% | -117.6% |
| Return on assets | -22.43% | 0% | 0% | -11.99% |
| Return on sales | -6919.06% | 0% | 0% | -8680.79% |
| Return on invested capital | 287.16% | 0% | 0% | -48.11% |
| Profitability | 50% | 0% | 50% | 0% |
| Total debt ratio | 28.85% | 0% | 0% | 77.42% |
| Debt ratio change over time | -0.86% | 0% | 0% | -0.81% |
| Dept financing | 9% | 0% | 25% | 25% |
| Current Ratio | 3.35% | 0% | 0% | 5.35% |
| Quick Ratio | 3.35% | 0% | 0% | 5.34% |
| Cash Position Ratio | 3.1% | 0% | 0% | 5.03% |
| Liquididy | 49% | 0% | 0% | 75% |
| Short-term ratios | AGLE | VLON | ELAT | RETA |
|---|---|---|---|---|
| Return on equity | 510.1% | 0% | 0% | 146.7% |
| Return on assets | -36.02% | 0% | 0% | -18.66% |
| Return on sales | -14683.38% | 0% | 0% | -28500.29% |
| Return on invested capital | 229.33% | 0% | 0% | -371.75% |
| Profitability | 50% | 0% | 50% | 7% |
| Total debt ratio | 50.22% | 0% | 0% | 108.07% |
| Debt ratio change over time | -0.76% | 0% | 0% | -1.53% |
| Dept financing | 12% | 0% | 25% | 25% |
| Current Ratio | 3.35% | 0% | 0% | 5.35% |
| Quick Ratio | 3.35% | 0% | 0% | 5.34% |
| Cash Position Ratio | 3.1% | 0% | 0% | 5.03% |
| Liquididy | 47% | 0% | 0% | 75% |